Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 -- Silo Pharma, Inc. , a developmental...

Related Keywords

Eric Weisblum ,Facebook ,Nasdaq ,Globenewswire Inc ,Columbia University ,Linkedin ,Silo Pharma Inc ,University Of Maryland ,New Drug Application ,Private Securities Litigation Reform Act ,Markets ,